Sanofi took a strike against attacks on the high prices of insulin products in its 2019 drug pricing report, claiming that the debate around insulin prices doesn't match the company's drug pricing history.
"Despite the rhetoric about skyrocketing insulin prices, the net price of insulin has been falling for five consecutive years, making our insulins significantly less expensive for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?